Small Interfering Rna (Sirna)

News

Related Video News

No related video news stories found.

Organic Broadcast Project

Related Videos

No related videos found.

Liquidia teams with Abbott

Published January 7, 2009, 11:49 pm, The News & Observer

Durham company has role in developing cancer treatment.

Discover News | Full Story


Liquidia Technologies to collaborate with Abbott on siRNA therapeutics

Published January 7, 2009, 3:37 pm, News-Medical-Net

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more ...

Discover News | Full Story


Liquidia Technologies Announces Collaboration with Abbott to Develop siRNA Therapeutics

Published January 7, 2009, 4:00 am, Business Wire via Yahoo! Finance

RESEARCH TRIANGLE PARK, N.C.----Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT® nanoparticles for the delivery of siRNA-based therapeutics.

Discover News | Full Story


Tekmira Partner Alnylam Files First IND For An RNAi Therapeutic Utilizing SNALP

Published January 5, 2009, 11:48 pm, PharmaceuticalOnline

Tekmira Pharmaceuticals Corporation announced recently that one of the company's collaborators, Alnylam Pharmaceuticals Inc., has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) seeking approval to begin a human clinical trial for a product candidate utilizing Tekmira's SNALP delivery technology.

Discover News | Full Story


Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO

Published January 5, 2009, 5:17 am, Centre Daily Times

Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside. Co-founder of ProlX Pharmaceuticals, Dr. Kirkpatrick was CEO from 1999 until its acquisition by Biomira Inc. in 2006. From 2006 through 2008 she ...

Discover News | Full Story


Ensysce Biosciences Inc. Appoints Dr. D. Lynn Kirkpatrick as President and CEO

Published January 5, 2009, 5:00 am, Business Wire via Yahoo! Finance

HOUSTON----Ensysce Biosciences Inc. announced today the appointment of Dr. Lynn Kirkpatrick as President and CEO. Dr. Kirkpatrick has an extensive background in targeted small molecule cancer drug development, and has brought three agents from bench to bedside.

Discover News | Full Story



News Directory

Get started fast by using a pre-defined news directory category

Breaking News
and Top Stories
Business
Earnings, Economy, Personal Finance, and Stock Markets
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss
Politics
Congress, Supreme Court, and White House
Science
Animals, Astronomy, Biotechnology, Space, and Weather
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis
Technology
Communications, Hardware, Internet, Personal Technology, and Software
United States
and Crimes and Trials
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East


© Copyright 2005-2006 News Meme, All Rights Reserved | More News | Link Index | OSWD Design

Powered by Odin Assemble 2.5a